Jco precision oncology.

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …Jan 6, 2022 · An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022. DOI: 10.1200/PO.21.00417 JCO Precision Oncology no. 6 (2022) e2100417. Published online March 23, 2022. PMID: 35319964. Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma Marion Oberlé, MD 1. x. Marion Oberlé. Search for articles by this author ...DOI: 10.1200/PO.21.00437 JCO Precision Oncology no. 6 (2022) e2100437. Published online January 27, 2022. Published online January 27, 2022. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature …

Limit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared. DOI: 10.1200/PO.18.00037 JCO Precision Oncology - published online July 23, 2018WebThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. …

In prior studies, 10% to 15% of MSI/dMMR colorectal cancer cases and 10% of MSI/dMMR endometrial cancer cases were caused by Lynch syndrome. 21,22,29 Lynch syndrome can increase the risk of many of the malignancies found to be MSI in the studies presented in JCO Precision Oncology; thus it is important for physicians to refer …

JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.28 Mar 2023 ... Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer. He begins by highlighting the ...Jan 6, 2022 · DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994 Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …JCO Precis Oncol. 2017; 1: ... To address these limitations, we describe OncoKB, a comprehensive precision oncology knowledge base that offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors to support optimal treatment decisions. OncoKB …

PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...

By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your …

DOI: 10.1200/PO.22.00197 JCO Precision Oncology no. 6 (2022) e2200197. Published online September 15, 2022. PMID: 36108259. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy ...DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...DOI: 10.1200/PO.21.00122 JCO Precision Oncology no. 5 (2021) 1354-1376. Published online August 25, 2021. Published online August 25, 2021. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsLimit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared. PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ... Limit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible.

DOI: 10.1200/PO.22.00580 JCO Precision Oncology no. 7 (2023) e2200580. Published online March 23, 2023. PMID: 36952646. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study Trisha Larkin, MD 1, 2. x. Trisha Larkin. …WebDOI: 10.1200/PO.21.00108 JCO Precision Oncology no. 5 (2021) 1151-1159. Published online July 15, 2021. Published online July 15, 2021. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisPURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...31 Aug 2022 ... Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017;2017.Mar 9, 2022 · PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ...

DOI: 10.1200/PO.20.00383 JCO Precision Oncology no. 5 (2021) 756-766. Published online May 3, 2021. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors Yuki Takeyasu, MD 1, 2. x. Yuki Takeyasu. Search for articles by this author; Hitomi S. Okuma, MD, PhD 1, 3. x. Hitomi S. Okuma ...Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ...

DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyAug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines.WebDOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …Looking for TASHKENT CITY ONCOLOGICAL DISPENSER. in Tashkent? - ☎️Phones ⚑Location of the company on the map, search for directions, how to get …DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812May 16, 2017 · Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ... From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care Lau-Min et al. Published online: February 17, 2021Regrettably, the proportion of patients with advanced cancer outstrip the specialty PC workforce capacity. 20 In the United States, there are currently about 1,700-3,300 full-time equivalents of board-certified PC specialists, most of whom are not oncology-specific, and care for patients with other serious illness. 21,22 Unfortunately, the current pipeline for future PC physicians is narrow ...

DOI: 10.1200/PO.17.00075 JCO Precision Oncology - published online October 10, 2017

DOI: 10.1200/PO.21.00417 JCO Precision Oncology no. 6 (2022) e2100417. Published online March 23, 2022. PMID: 35319964. Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma Marion Oberlé, MD 1. x. Marion Oberlé. Search for articles by this author ...

DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyDOI: 10.1200/PO.22.00517 JCO Precision Oncology no. 6 (2022) e2200517. Published online November 12, 2022. PMID: 36370464. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer Sarah E. Coughlin, MD 1. x. Sarah E. Coughlin. Search for articles by this author ...In prior studies, 10% to 15% of MSI/dMMR colorectal cancer cases and 10% of MSI/dMMR endometrial cancer cases were caused by Lynch syndrome. 21,22,29 Lynch syndrome can increase the risk of many of the malignancies found to be MSI in the studies presented in JCO Precision Oncology; thus it is important for physicians to refer …DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994WebDOI: 10.1200/PO.22.00621 JCO Precision Oncology no. 7 (2023) e2200621. Published online February 21, 2023. Published online February 21, 2023. Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS G12C -Mutant Non–Small-Cell Lung CancerPURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...JCO Precision Oncology Conversations is a monthly podcast featuring conversations with authors of clinically relevant and significant articles published in the …PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ...DOI: 10.1200/PO.22.00197 JCO Precision Oncology no. 6 (2022) e2200197. Published online September 15, 2022. PMID: 36108259. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy ...

Apr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ... Precision oncology, where patients are given therapies on the basis of their genomic profile and disease trajectory, is rapidly evolving to become a pivotal part of cancer management, supported by the approval of many biomarker-matched targeted therapies and cancer immunotherapies by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 1 Driven by recent advances in ...DOI: 10.1200/PO.20.00110 JCO Precision Oncology no. 4 (2020) 823-824. Published online July 16, 2020. PMID: 35050756. Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion Samuel A. Urrutia Argueta, MD 1. x. Samuel A. Urrutia Argueta. Search for articles by this author ...Instagram:https://instagram. jpie etfgle coupe 2024securepark10 year municipal bond rates DOI: 10.1200/PO.20.00257 JCO Precision Oncology no. 4 (2020) 1393-1402. Published online November 16, 2020. Published online November 16, 2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies15 Mar 2023 ... Elypta study published in JCO Precision Oncology using GAGome to predict and monitor responses of patients with Metastatic Renal Cell ... big ryan eggbkln etf DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyDOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812 dental insurance plans ma The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...May 18, 2021 · As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...